Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Daru ; 28(1): 119-130, 2020 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-31902097

RESUMEN

PURPOSE: The aim of this study was to create and assess biological activity of a new compound based on carnosine and acetylsalicylic acid (ASA) that will comprise antioxidant effect with antiplatelet activity, while simultaneously preventing side effects on the gastrointestinal tract. METHODS: Salicyl-carnosine (SC) was synthesized by condensation of ASA and carnosine. Antioxidant activity was determined by spectrophotometric and chemiluminescence methods. Antiplatelet activity was carried out by the light transmission-aggregometry method using the inductor ADP. Chronic gastric ulcer in rats was modeled using glacial acetic acid. RESULTS: Using SOD-like activity, iron-induced chemiluminescence, BaSO4-activated respiratory burst, and evaluation of red blood cell structure stabilization during oxidative damage induced by sodium hypochlorite, it was shown that SC possesses antioxidant activity analogous, or better, than that of carnosine. Antiplatelet activity of SC was evaluated in the blood of healthy individuals, and was also shown to be comparable to, or exceeding that of ASA. Also SC demonstrates high resistance to hydrolysis by tissue and serum carnosinases. Most importantly, it was shown that SC has protected the gastric mucosa against the formation of stomach ulcerative lesions and promoted their epithelization, therefore overcoming the undesirable inherent side effects of ASA. CONCLUSIONS: SC preserves pharmacologically significant properties of ASA and carnosine while retaining an anti-ulcer activity and resistance to the carnosinase hydrolysis at the same time. These properties are particularly promising for the potential development of new anti-inflammatory and antithrombotic drugs. Graphical abstract .


Asunto(s)
Antiulcerosos , Antioxidantes , Aspirina , Carnosina , Inhibidores de Agregación Plaquetaria , Ácido Acético , Animales , Antiulcerosos/química , Antiulcerosos/farmacología , Antiulcerosos/uso terapéutico , Antioxidantes/química , Antioxidantes/farmacología , Antioxidantes/uso terapéutico , Aspirina/análogos & derivados , Aspirina/química , Aspirina/farmacología , Aspirina/uso terapéutico , Carnosina/análogos & derivados , Carnosina/química , Carnosina/farmacología , Carnosina/uso terapéutico , Eritrocitos/efectos de los fármacos , Hemólisis/efectos de los fármacos , Humanos , Hidrólisis , Leucocitos/efectos de los fármacos , Masculino , Agregación Plaquetaria/efectos de los fármacos , Inhibidores de Agregación Plaquetaria/química , Inhibidores de Agregación Plaquetaria/farmacología , Inhibidores de Agregación Plaquetaria/uso terapéutico , Ratas Wistar , Estallido Respiratorio/efectos de los fármacos , Úlcera Gástrica/inducido químicamente , Úlcera Gástrica/tratamiento farmacológico , Superóxidos/química
2.
Int J Mol Sci ; 19(1)2018 Jan 02.
Artículo en Inglés | MEDLINE | ID: mdl-29301276

RESUMEN

An antidiabetic drug of the thiazolidinedione class, rosiglitazone (RG) demonstrates anti-inflammatory properties in various brain pathologies. The mechanism of RG action in brain cells is not fully known. To unravel mechanisms of RG modulation of toll-like receptor (TLR) signaling pathways, we compare primary rat neuron and astrocyte cultures stimulated with the TLR4 agonist lipopolysaccharide (LPS) and the TLR3 agonist poly I:C (PIC). Both TLR agonists induced tumor necrosis factor (TNFα) release in astrocytes, but not in neurons. Neurons and astrocytes released interleukin-10 (IL-10) and prostaglandin E2 (PGE2) in response to LPS and PIC. RG decreased TLR-stimulated TNFα release in astrocytes as well as potentiated IL-10 and PGE2 release in both astrocytes and neurons. RG induced phosphorylation of p38 and JNK MAPK (mitogen-activated protein kinase) in neurons. The results reveal new role of RG as a modulator of resolution of neuroinflammation.


Asunto(s)
Astrocitos/metabolismo , Neuronas/metabolismo , Transducción de Señal/efectos de los fármacos , Tiazolidinedionas/farmacología , Receptor Toll-Like 3/metabolismo , Receptor Toll-Like 4/metabolismo , Animales , Astrocitos/efectos de los fármacos , Células Cultivadas , Corteza Cerebral/citología , Dinoprostona/metabolismo , Interleucina-10/metabolismo , Proteínas Quinasas JNK Activadas por Mitógenos/metabolismo , Neuronas/efectos de los fármacos , Neuronas/enzimología , Fosforilación/efectos de los fármacos , Ratas Wistar , Rosiglitazona , Factor de Necrosis Tumoral alfa/metabolismo , Proteínas Quinasas p38 Activadas por Mitógenos/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...